Agc Biologics Inc.
Agc Biologics Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States, with significant operational facilities across Europe and Asia. Founded in 2018, the company has quickly established itself as a leader in contract development and manufacturing, specialising in the production of complex biologics, including monoclonal antibodies and recombinant proteins. Agc Biologics is renowned for its state-of-the-art facilities and commitment to quality, offering a comprehensive range of services from cell line development to commercial manufacturing. The company’s unique approach combines advanced technology with a customer-centric focus, ensuring tailored solutions that meet the specific needs of its clients. With a strong market position and a reputation for excellence, Agc Biologics continues to drive innovation in the biopharmaceutical sector.
DitchCarbon Score
How does Agc Biologics Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Agc Biologics Inc.'s score of 8 is higher than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Agc Biologics Inc.'s reported carbon emissions
In 2023, Agc Biologics Inc. reported total carbon emissions of approximately 1,132,000 kg CO2e from Scope 1 and 378,000 kg CO2e from Scope 2. This reflects a slight increase in Scope 1 emissions compared to 2022, where they were about 1,031,000 kg CO2e, while Scope 2 emissions decreased from approximately 816,000 kg CO2e in the previous year. The company has not disclosed any specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. However, the ongoing monitoring of emissions indicates a commitment to understanding and managing their carbon footprint. As Agc Biologics continues to navigate the complexities of climate impact, their emissions data highlights the importance of transparency and accountability in their environmental strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 1,066,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 739,000 | 000,000 | 000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Agc Biologics Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
